Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

MetAL trial for prostate cancer

Dr Mieke Van Hemelrijck - Kings College London, London, UK

MetAL trial for prostate cancer ( Dr Mieke Van Hemelrijck - Kings College London, London, UK )

Prostate cancer screening: A north/south comparison in Ireland

Dr Anna Gavin - Queen's University Belfast, Belfast, UK

Prostate cancer screening: A north/south comparison in Ireland ( Dr Anna Gavin - Queen's University Belfast, Belfast, UK )

Editor's ASCO 2016 Roundup

Prof Gordon McVie - ecancer Editor in Chief

Editor's ASCO 2016 Roundup ( Prof Gordon McVie - ecancer Editor in Chief )

ASCO 2016: Current treatment approaches for advanced prostate cancer

Prof Przemyslaw Twardowski and Prof Gordon McVie

ASCO 2016: Current treatment approaches for advanced prostate cancer ( Prof Przemyslaw Twardowski and Prof Gordon McVie )

Checkpoint inhibitor therapy benefits advanced bladder cancer patients

Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA

Checkpoint inhibitor therapy benefits advanced bladder cancer patients ( Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA )

Adjuvant docetaxel fails after radical prostatectomy for high risk prostate...

Dr Goran Ahlgren - Lund University, Malmö, Sweden

Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer ( Dr Goran Ahlgren - Lund University, Malmö, Sweden )

MyPathway guidance of targeted therapy based on molecular profiles

Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA

MyPathway guidance of targeted therapy based on molecular profiles ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )

Testing the safety and efficacy of the PD-L1 antibody durvalumab

Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Testing the safety and efficacy of the PD-L1 antibody durvalumab ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )

ASCO 2016: Accuracy of multi-parametric MRI to predict further investigational...

Prof Nick James and Prof Charles Ryan

ASCO 2016: Accuracy of multi-parametric MRI to predict further investigational biopsy ( Prof Nick James and Prof Charles Ryan )

ASCO 2016: Highlights in prostate cancer from days 3 and 4

Dr Eleni Efstathiou, Prof Kurt Miller, Dr Chris Parker and Prof Stephane Oudard

ASCO 2016: Highlights in prostate cancer from days 3 and 4 ( Dr Eleni Efstathiou, Prof Kurt Miller, Dr Chris Parker and Prof Stephane Oudard )

ASCO 2016: Advances in Prostate Cancer

Prof Karim Fizazi, Prof Maria De Santis, Prof Bertrand Tombal and Dr Mark...

ASCO 2016: Advances in Prostate Cancer ( Prof Karim Fizazi, Prof Maria De Santis, Prof Bertrand Tombal and Dr Mark Beresford )

Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

More from ecancer